StockData
Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc. (ELVN) stock

ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$46.85−0.77 (-1.62%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Enliven Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Enliven Therapeutics's enterprise value was $2.85B on Nov 11, 2026, against $802.44M a year earlier. Over the last 5 years it ranged from -$85.27M to $3.35B, with a median of $581.82M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$2.85B+556.2%
2025Dec 31, 2025$435.02M-43.6%
2024Dec 31, 2024$771.42M+151.5%
2023Dec 29, 2023$306.78M–
2022Dec 30, 2022-$4.69M–
2021Dec 31, 2021-$74.42M-184.7%
2020Dec 31, 2020$87.82M–

More Enliven Therapeutics figures

See a number that looks wrong?